Johnson & Johnson (JNJ) is making a $3.05 billion bet on the future of cancer treatment. The pharmaceutical giant announced Monday it's acquiring Halda Therapeutics OpCo, Inc., a clinical-stage biotech company with some interesting technology for tackling solid tumors.

What's Halda bringing to the table? A proprietary platform called Regulated Induced Proximity Targeting Chimera (RIPTAC, because biotech loves acronyms) that's designed to develop oral, targeted therapies for multiple types of solid tumors, with a particular focus on prostate cancer.

The star of the show is HLD-0915, a clinical-stage therapy specifically aimed at prostate cancer. The transaction should wrap up within the next few months, assuming the usual regulatory hurdles don't pop up.

"This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth," said Jennifer Taubert, executive vice president and worldwide chairman of Innovative Medicine at Johnson & Johnson.

There's a near-term cost, though. The company expects the deal to ding adjusted earnings per share by 15 cents in 2026, thanks to short-term financing costs and a non-recurring charge related to equity awards for Halda employees when the deal closes. That's the price of admission for what J&J clearly sees as a valuable addition to its cancer-fighting arsenal.

Tremfya Keeps Winning

Also on Monday, J&J dropped some encouraging news about Tremfya, one of its existing blockbusters. New data from the Phase 3b APEX study shows the drug continued to reduce both signs and symptoms of active psoriatic arthritis and inhibit progression of structural damage at 48 weeks.

The data, presented at the Inflammatory Skin Disease Summit 2025, showed that at Week 24, Tremfya demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo. That held true whether patients received the drug every four weeks or every eight weeks, giving doctors some dosing flexibility.

Perhaps more importantly, Tremfya showed continued clinically meaningful improvement in American College of Rheumatology response criteria (ACR50) rates. Those response rates actually increased from Week 24 to Week 48 in both dose groups, suggesting the benefits build over time rather than plateau.

Even patients who started on placebo and then switched to Tremfya at Week 24 caught up remarkably well. Nearly half of them achieved ACR50 response by Week 48, and the inhibition of structural joint damage was sustained through the full 48-week period.

Johnson & Johnson stock was up 1.90% at $199.58 on Monday following the announcements.